Indivior Pharmaceuticals (INDV) Capital Expenditures (2024 - 2026)

Indivior Pharmaceuticals' Capital Expenditures history runs 3 years deep, the most recent figure standing at $20.0 million for Q1 2026.

• In Q1 2026, Capital Expenditures rose 300.0% year-over-year to $20.0 million; the TTM figure through Mar 2026 stood at $81.0 million (up 153.12% YoY), while the FY2025 annual figure was $66.0 million, up 127.59% from the prior year.
• Capital Expenditures was $20.0 million for Q1 2026 at Indivior Pharmaceuticals, down from $24.0 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $24.0 million in Q4 2025 to a low of $2.0 million in Q1 2024.
• Historically, Capital Expenditures has averaged $12.8 million across 3 years, with a median of $16.0 million in 2024.
• Biggest YoY gain for Capital Expenditures was 325.0% in 2025; the steepest drop was 50.0% in 2025.
• A 3-year view of Capital Expenditures shows it stood at $16.0 million in 2024, then surged by 50.0% to $24.0 million in 2025, then retreated by 16.67% to $20.0 million in 2026.
• The last three Capital Expenditures figures came in at $20.0 million (Q1 2026), $24.0 million (Q4 2025), and $20.0 million (Q3 2025), per Business Quant data.